Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3282063 | Clinical Gastroenterology and Hepatology | 2013 | 10 Pages |
Abstract
Acute liver injury caused by TNF-α antagonists may be a class effect because multiple agents in this category have been implicated. The most common presentation is an autoimmune phenotype with marked hepatocellular injury, but a mixed non-autoimmune pattern or predominant cholestasis also occurs. The prognosis is usually good after drug discontinuation, although some patients may benefit from a course of corticosteroids. ClinicalTrials.gov: Number, NCT00345930
Keywords
ASMAALTRUCAMAIHINRASTAspartate aminotransferaseDrug-induced liver injuryAlanine aminotransferaseAlkaline phosphataseantinuclear antibodyanti–smooth muscle antibodyANAimmunoglobulin tumor necrosis factor–αautoimmunityDILIDILINHepatotoxicitytumor necrosis factorTNF-αInternational Normalized RatioAutoimmune hepatitis
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Marwan Ghabril, Herbert L. Bonkovsky, Clarissa Kum, Tim Davern, Paul H. Hayashi, David E. Kleiner, Jose Serrano, Jim Rochon, Robert J. Fontana, Maurizio Bonacini, U.S. Drug-Induced Liver Injury Network U.S. Drug-Induced Liver Injury Network,